{
    "nct_id": "NCT05311618",
    "official_title": "A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.\n* Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type for which the patient was eligible and willing to receive.\n* Adequate bone marrow, kidney and liver function\n* Performance status of 0 or 1.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "â€¢ Prior treatment targeting LAIR1",
    "miscellaneous_criteria": ""
}